Результати пошуку - Victoria Lock

  • Показ 1 - 4 результатів із 4
Уточнити результати
  1. 1
    A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

    A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors за авторством Daruka Mahadevan, Ruth Plummer, Matthew Squires, Diane Rensvold, Sandra Kurtin, Chris Pretzinger, Tomislav Dragovich, Joëlla W. Adams, Victoria Lock, Donna-Michelle Smith, D. Von Hoff, Hilary Calvert

    Опубліковано 2011
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

    A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies за авторством Hendrik‐Tobias Arkenau, Ruth Plummer, L. Rhoda Molife, David Olmos, Timothy A. Yap, Matthew Squires, Sara Lewis, Victoria Lock, Murray Yule, John F. Lyons, Hilary Calvert, Ian Judson

    Опубліковано 2011
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth

    AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth за авторством Kyla M. Grimshaw, Lisa-Jane K. Hunter, Timothy A. Yap, Simon P. Heaton, Mike I. Walton, Steven J. Woodhead, Lynsey Fazal, Matthias Reule, Thomas G. Davies, Lisa C. A. Seavers, Victoria Lock, John F. Lyons, Neil T. Thompson, Paul Workman, Michelle D. Garrett

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

    A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study за авторством Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell‐Hewson, Guy Makin, Sarah Halford, Gary D Acton, Philip Ross, Shamim Kazmi-Stokes, Victoria Lock, Ana Isabel Enríquez Rodríguez, John F. Lyons, Alan V. Boddy, Melanie J. Griffin, Murray Yule, Darren Hargrave

    Опубліковано 2014
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: